Segall Bryant & Hamill’s Celldex Therapeutics CLDX Stock Holding History

Segall Bryant & Hamill’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Sell	336,291 -10,628	-3%	-$343K	0.15%	223
2026 Q1	$11M	Sell	346,919 -167,612	-33%	-$4.57M	0.16%	215
2025 Q4	$14M	Sell	514,531 -14,066	-3%	-$370K	0.19%	184
2025 Q3	$13.7M	Buy	528,597 +140,709	+36%	+$3.26M	0.18%	189
2025 Q2	$7.89M	Buy	+387,888	New	+$7.55M	0.11%	263

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's CLDX Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its Celldex Therapeutics (CLDX) stake by 3.1% in Q2 2026, selling an estimated $343K and leaving 336,291 shares worth $12.5M. The position accounts for 0.15% of the portfolio, ranked #223.

Segall Bryant & Hamill first reported a position in CLDX in Q2 2025 and has held it in 5 quarters since. The position peaked at $14M in Q4 2025. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Segall Bryant & Hamill held 336,291 shares of Celldex Therapeutics worth $12.5M as of Q2 2026.
Segall Bryant & Hamill sold 10,628 Celldex Therapeutics shares in Q2 2026, an estimated $343K.
Celldex Therapeutics made up 0.15% of Segall Bryant & Hamill's portfolio in Q2 2026, its #223 holding.
Segall Bryant & Hamill first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 5 quarters since.
Segall Bryant & Hamill's Celldex Therapeutics position peaked at $14M in Q4 2025.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.